Active ingredientFostamatinibCat. No. P-F124-001CAS 901119-35-5Family · Pharmaceutical analytical standards
Fostamatinib
An inhibitor of the SYK kinase, considered by the FDA a first-in-class medicine: it was approved in the US in 2018 and in the European Union in 2020 for chronic immune thrombocytopenia (ITP) in adults. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It is a prodrug: in the gut the enzyme alkaline phosphatase removes its phosphate group and releases the real active molecule, tamatinib.
Go to the active ingredient →Active ingredientFostamatinibCat. No. P-F124-001CAS 901119-35-5
Isotopically labelledFostamatinib Impurity 1-13C-d3Cat. No. P-F124-002
Isotopically labelledFostamatinib-13C-d3Cat. No. P-F124-003
NitrosamineN1-Nitroso FostamatinibCat. No. P-F124-004
NitrosamineN2-Nitroso FostamatinibCat. No. P-F124-005
ImpurityTamatinibCat. No. P-F124-006CAS 841290-80-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.